ReNetX Bio Reports Topline Study Results

New Haven, Conn., Oct. 5, 2022 -- ReNetX Bio, Inc., a privately held, clinical-stage biotechnology company committed to reversing disease and damage for patients suffering from ophthalmological and neurological disorders, announces topline results from Part 2 of the RESET multiple-dose study in patients with chronic spinal cord injury.

AXER-204 was demonstrated to be generally safe and well-tolerated, with no relevant safety issues observed over 4 months of intrathecal dosing in individuals with chronic cervical spinal cord injury [AIS grades A (complete) AIS grades B, C, and D (incomplete)], recruited more than one year after their trauma. Efficacy endpoints were changes in function and patient-reported outcomes from baseline to 6 months post-baseline. AXER-204, compared to placebo, did not achieve statistically significant benefit for the prespecified primary or secondary efficacy endpoints in the completed study. "ReNetX Bio will complete full analyses of the RESET study including final 9-month assessments, the evaluation of positive trends in post hoc subsets in patients with incomplete injury, and the presence of biomarkers for target engagement and synaptic plasticity" according to Dr. Stephen Strittmatter, Chair of Yale Neuroscience and ReNetX Scientific Founder.

"While we plan our next steps, we are especially excited about the positive biomarker trends supporting improved plasticity. I want to applaud our team's hard work and commitment in executing this robust study," said Erika R. Smith, Chief Executive Officer of ReNetX Bio. Dr. George Maynard, President and Chief Scientific Officer added, "We are deeply grateful to the participants, caregivers, and researchers who made the RESET study possible. We are committed to understanding the totality of the RESET results and we intend to report the complete data, at future scientific meetings and in publications, when they are available."

ReNetX Bio will continue to advance efforts with AXER-204 with particular focus on the compelling portfolio programs in ophthalmology, leveraging extensive preclinical evidence in currently unaddressed optic nerve and retinal disorders by enhancing cell survival and neuroplasticity.

About the RESET Study: For more information, see ClinicalTrials.gov
About ReNetX Bio, Inc.: For more information, please visit www.renetx.com

This study is supported by Wings for Life Foundation and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number R44NS118974. Preclinical development of AXER-204 was supported in part by the Therapeutic Development Branch in the intramural Division of Preclinical Innovation of the National Center for Advancing Translational Sciences at NIH.